^
Association details:
| Biomarker: | TP53 mutation + KRAS mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer
Published date:
03/02/2021
Excerpt:
...We validated the predictive effect of TP53/KRAS co‐mutation in the Rizvi cohort and found that the PFS of patients with TP53/KRAS co‐mutation was superior to that of TP53‐MUT/KRAS‐WT, TP53‐WT/KRAS‐MUT, and TP53/KRAS co‐WT patients (median PFS: 5.77, 3.6, 2.33, and 2.6 months, respectively, p = 0.006....TP53 mutation combined with KMT2C or KRAS mutation was a better biomarker with expanded population benefit from ICIs therapy and increased the predictive power
DOI:
10.1002/cam4.3649
Source:
Title:
Interdependence of KRAS and TP53 mutations in predicting benefit from immune checkpoint inhibitor (ICI) in non-squamous NSCLC
Published date:
09/14/2020
Excerpt:
...higher ORR was linked with KRAS/TP53 mutation, while longer PFS was merely associated with the mutation in TP53 (HR 0.72, 95%CI 0.55-0.95, P=0.019), but not KRAS (P=0.295). TP53 mutation brought improvement of ORR and PFS in patients with KRAS mutation (ORR, p=0.002; PFS, p<0.001), but not KRAS-WT population (ORR, p=0.104; PFS, p=0.566). KRAS mutation was associated with better ORR and PFS in TP53-mut (ORR, p=0.011; PFS, p=0.017), but not TP53-WT population (ORR, p=0.518; PFS, p=0.885). We further investigated the predictive efficacy of the co-mutation of TP53 and KRAS, and observed remarkably improved ORR (2.59-fold, P<0.001) and PFS (HR 0.47, 95%CI 0.32-0.68, P=0.001) in co-mutated patients. Co-mutation of KRAS and TP53 is identified as a potential immunotherapeutic predictor of better ORR and PFS in patients with EGFR/ALK WT non-squamous NSCLC.
Source:
Title:
Efficacy of immunotherapy as second-line or later-line therapy and prognostic significance of KRAS and/or TP53 mutations in advanced non-small cell lung cancer patients
Published date:
04/05/2023
Excerpt:
NSCLC patients with KRAS and/or TP53 mutations treated with ICIs showed significantly higher objective response rate, disease control rate, PFS, and OS compared to NSCLC patients with wild-type KRAS/TP53 (P < 0.05).
DOI:
10.1097/CEJ.0000000000000799
Source:
Title:
KRAS mutation predict response and outcome in advanced non-small cell lung carcinoma without driver alterations receiving PD-1 blockade immunotherapy combined with platinum-based chemotherapy: a retrospective cohort study from China
Published date:
10/10/2022
Excerpt:
Patients with advanced NSCLC without driver alterations who were treated with ICI and platinum-based chemotherapy (N=80) were identified....The OS and PFS of patients with KRAS mutations were significantly higher than those in the non-KRAS mutant group (P<0.05)....This work provides evidence that KRAS mutation in advanced NSCLC may be served as a potential predictive biomarker for immunotherapeutic efficacy.
Secondary therapy:
Chemotherapy
DOI:
10.21037/tlcr-22-655
Source:
Title:
Molecular Characteristics and the Effect of KRAS Mutation on the Prognosis of Immunotherapy in Non-Small Cell Lung Cancer in Xinjiang, China
Published date:
09/21/2022
Excerpt:
...while patients with TP53 and KRAS co-mutation had the best immunotherapy effect, which was better than KRAS mutation alone…
DOI:
https://doi.org/10.2147/OTT.S381825
